Sientra, Inc. (SIEN) Given Average Recommendation of “” by Analysts
Shares of Sientra, Inc. (NASDAQ:SIEN) have earned a consensus broker rating score of 1.80 (Buy) from the five analysts that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold rating and three have assigned a strong buy rating to the company. Sientra’s rating score has improved by 22.7% in the last 90 days as a result of various analysts’ ratings changes.
Analysts have set a 1 year consensus price objective of $13.00 for the company and are expecting that the company will post ($0.63) earnings per share for the current quarter, according to Zacks. Zacks has also given Sientra an industry rank of 107 out of 265 based on the ratings given to its competitors.
A number of research analysts recently issued reports on SIEN shares. Zacks Investment Research downgraded shares of Sientra from a “hold” rating to a “sell” rating in a research note on Tuesday, August 15th. ValuEngine upgraded shares of Sientra from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Lake Street Capital reiterated a “buy” rating and issued a $15.00 price target (up previously from $11.00) on shares of Sientra in a research note on Tuesday, August 8th. Stephens started coverage on shares of Sientra in a research note on Tuesday, July 11th. They issued an “overweight” rating and a $12.00 price target for the company. Finally, Canaccord Genuity started coverage on shares of Sientra in a research note on Monday. They issued a “buy” rating and a $14.00 price target for the company.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Cannell Capital LLC increased its stake in shares of Sientra by 2.3% in the first quarter. Cannell Capital LLC now owns 1,139,571 shares of the medical instruments supplier’s stock valued at $9,595,000 after buying an additional 26,000 shares in the last quarter. Gilder Gagnon Howe & Co. LLC increased its stake in shares of Sientra by 36.3% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,114,511 shares of the medical instruments supplier’s stock valued at $10,833,000 after buying an additional 296,902 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of Sientra by 18.0% in the first quarter. Ameriprise Financial Inc. now owns 659,859 shares of the medical instruments supplier’s stock valued at $5,555,000 after buying an additional 100,445 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Sientra by 11.2% in the second quarter. Vanguard Group Inc. now owns 590,311 shares of the medical instruments supplier’s stock valued at $5,737,000 after buying an additional 59,546 shares in the last quarter. Finally, Cloverdale Capital Management LLC increased its stake in shares of Sientra by 28.9% in the second quarter. Cloverdale Capital Management LLC now owns 492,237 shares of the medical instruments supplier’s stock valued at $4,785,000 after buying an additional 110,495 shares in the last quarter. Institutional investors own 77.61% of the company’s stock.
Shares of Sientra (SIEN) traded up 1.69% during trading on Monday, hitting $11.41. 28,963 shares of the company’s stock were exchanged. Sientra has a one year low of $6.92 and a one year high of $11.47. The firm has a 50-day moving average price of $10.63 and a 200-day moving average price of $9.08. The stock’s market cap is $220.28 million.
Sientra (NASDAQ:SIEN) last issued its quarterly earnings results on Wednesday, August 9th. The medical instruments supplier reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.04. Sientra had a negative net margin of 173.83% and a negative return on equity of 52.30%. The company had revenue of $8.20 million during the quarter, compared to the consensus estimate of $6.97 million. The business’s quarterly revenue was up 32.3% compared to the same quarter last year. Equities research analysts expect that Sientra will post ($3.04) EPS for the current fiscal year.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related stocks with our FREE daily email newsletter.